Cargando…
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
The main aim of phase I trials is to evaluate the tolerability and pharmacology of a new compound. However, investigating the potential for clinical benefit is also a key objective. Our phase I trial portfolio incorporates a range of new drugs, including molecular targeted agents, sometimes given to...
Autores principales: | Arkenau, H-T, Olmos, D, Ang, J E, de Bono, J, Judson, I, Kaye, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275488/ https://www.ncbi.nlm.nih.gov/pubmed/18349817 http://dx.doi.org/10.1038/sj.bjc.6604218 |
Ejemplares similares
-
Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience
por: Olmos, D, et al.
Publicado: (2008) -
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
por: Tirelli, U
Publicado: (2008) -
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
por: Postel-Vinay, S, et al.
Publicado: (2009) -
Treatment of Epithelioid Sarcoma at the Royal Marsden Hospital
por: Livi, L., et al.
Publicado: (2003) -
Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
por: Swerdlow, A. J., et al.
Publicado: (1997)